Methicillin-Resistant Staphylococcus aureus in Poultry and Poultry Meat: A Meta-Analysis

ABSTRACT Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that colonizes and infects various host species and has been found in the poultry production chain, raising concerns about possible transmission from farm to fork. The objective of this study was to use meta-analytical methods to estimate the pooled prevalence of MRSA in chickens, turkeys, chicken meat, and turkey meat. Three electronic databases (PubMed, LILACS, and SciELO) were searched to establish MRSA prevalence from 51 studies published from 2003 through May 2017. The heterogeneity was assessed, and the pooled MRSA prevalence was calculated by using the random effects model according to the method of DerSimonian and Laird. Pooled MRSA prevalence (95% confidence interval [CI]) in turkeys, turkey meat, broilers, and chicken meat was 36% (1 to 78%), 13% (1 to 28%), 5% (2 to 9%), and 5% (3 to 8%), respectively. South America had the highest MRSA prevalence (27%; 95% CI, 17 to 37%), and North America had the lowest (1%; 95% CI, 0 to 2%). Livestock-associated MRSA has been isolated from poultry and poultry meat, indicating that this variant can spread from farm to fork. The presence of MRSA in poultry and poultry meat poses risks to public health, and steps should be taken to mitigate the contamination and spread of this bacterium along the poultry production chain.

Download Full-text

Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis

10.21203/rs.3.rs-38902/v2 ◽

2020 ◽

Author(s):

Zhouqi Li ◽

Hemu Zhuang ◽

Guannan Wang ◽

Hui Wang ◽

Ying Dong

Keyword(s):

Staphylococcus Aureus ◽

Cancer Patients ◽

Methicillin Resistant Staphylococcus Aureus ◽

Eastern Mediterranean ◽

Meta Analysis ◽

Bloodstream Infections ◽

Systemic Review ◽

Primary Data ◽

Methicillin Resistant ◽

Pooled Prevalence

Abstract Background: Cancer patients are more likely to develop and die of bloodstream infection (BSI) than noncancer patients. Methicillin-resistant Staphylococcus aureus (MRSA), which is associated with immense mortality and economic burden worldwide, is not covered by the recommended initial antibiotic therapy for cancer patients with BSI. This systemic review was performed to estimate the global methicillin-resistant Staphylococcus aureus (MRSA) prevalence among bacteremia in patients with malignancy, and further study the predictors and mortality of cancer patients with MRSA bacteremia.Methods: The PubMed and EMBASE databases were searched for studies published from Jan. 2000 to Mar. 2020 that provided primary data on the prevalence, predictors, or mortality of MRSA bacteremia in cancer patients. A random-effects model meta-analysis was performed to estimate the pooled prevalence of MRSA with 95% confidence intervals (95% CIs).Results: The pooled prevalence of MRSA was 3% (95% CI 2–5%) among all bloodstream infections (BSIs) and 44% (95% CI 32–57%) among S. aureus bacteremia in cancer patients. Based on geographical stratification, the pooled prevalence was 5% in Africa (95% CI 1–14%), 1% in Americas (95% CI 1–2%), 2% in Europe (95% CI 1–4%), 4% in Western Pacific (95% CI 2–7%), 8% in South-east Asia (95% CI 4–14%) and 0% in Eastern Mediterranean (95% CI 0–3%). No significant temporal change in MRSA rates was detected in this analysis (R2 = 0.06; P=0.24). Predictors for MRSA BSIs among cancer patients were identified by comparison with their methicillin-susceptible counterparts, and they were mainly related to healthcare-associated infections and immunosuppression. Finally, the 60-day mortality in adult cancer patients with MRSA BSIs was reported to be 12%, and the 6-month overall mortality was 43.2%, with community-onset infection, secondary BSI, and vancomycin MIC≥2g/mL being the risk factors for mortality.Conclusions: Although the prevalence of MRSA BSIs among cancer patients is relatively low, it did not decline over time as MRSA BSIs in the general hospital population and the high mortality rate was related to MRSA BSIs in patients with malignancy.

Download Full-text

Prevalence of Methicillin-Resistant Staphylococcus Aureus (MRSA) infection in patients with Cystic Fibrosis: a meta-analysis

10.21203/rs.2.11668/v1 ◽

2019 ◽

Author(s):

Sagad Omer Obeid Mohamed ◽

Almigdad H. M. Ali ◽

Abazr A. H. Ibrahim ◽

Mahmoud Elnil ◽

Almutasim B. E. Elhassan ◽

...

Keyword(s):

Cystic Fibrosis ◽

Staphylococcus Aureus ◽

Methicillin Resistant Staphylococcus Aureus ◽

Meta Analysis ◽

Healthcare Providers ◽

Inclusion Criteria ◽

Methicillin Resistant ◽

Pooled Prevalence ◽

Mrsa Infection ◽

Meta Analyses

Abstract Background Methicillin-resistant staphylococcus aureus (MRSA) infection is increasingly being reported among patients with cystic fibrosis (CF) and contributes to pulmonary morbidity in CF, with poorer prognosis. The aim of this study was to assess the prevalence of MRSA infection in patients with CF. Methods We conducted this study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases of MEDLINE/PubMed, WHO-Virtual Health Library (VHL), ScienceDirect, Google Scholar and OpenGrey were searched to recruit the relevant articles. Pooled prevalence with the corresponding 95% confidence interval (CI) was calculated using OpenMeta Analyst software, and heterogeneity among studies was estimated using the I2 statistics. Results According to our inclusion criteria, 27 studies included a total of 47,413 patients were analyzed. The pooled prevalence of MRSA in patients with CF was 15.2% (95% CI 9.70%– 20.7%). Subgroup analyses and meta-regression showed that the prevalence of MRSA in patients with CF was significantly associated with different geographical areas (P<0.001), data collection method (P<0.001), sample obtaining source (P<0.001), and study year (P = 0.006). Conclusions prevalence of MRSA infection is increasing in patients with CF. the results of this study could provide a reference for further controlling transmission and the management of patients with CF. Healthcare providers need to be aware of the clinically important association between MRSA infection and CF to ensure effective management.

Download Full-text

Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis

10.21203/rs.3.rs-38902/v3 ◽

2021 ◽

Author(s):

Zhouqi Li ◽

Hemu Zhuang ◽

Guannan Wang ◽

Hui Wang ◽

Ying Dong

Keyword(s):

Staphylococcus Aureus ◽

Cancer Patients ◽

Methicillin Resistant Staphylococcus Aureus ◽

Eastern Mediterranean ◽

Meta Analysis ◽

Bloodstream Infections ◽

Systemic Review ◽

Primary Data ◽

Methicillin Resistant ◽

Pooled Prevalence

Abstract Background: Cancer patients are more likely to develop and die of bloodstream infection (BSI) than noncancer patients. Methicillin-resistant Staphylococcus aureus (MRSA), which is associated with immense mortality and economic burden worldwide, is not covered by the recommended initial antibiotic therapy for cancer patients with BSI. This systemic review was performed to estimate the global methicillin-resistant Staphylococcus aureus (MRSA) prevalence among bacteremia in patients with malignancy, and further study the predictors and mortality of cancer patients with MRSA bacteremia. Methods: The PubMed and EMBASE databases were searched for studies published from Jan. 2000 to Mar. 2020 that provided primary data on the prevalence, predictors, or mortality of MRSA bacteremia in cancer patients. A random-effects model meta-analysis was performed to estimate the pooled prevalence of MRSA with 95% confidence intervals (95% CIs).Results: The pooled prevalence of MRSA was 3% (95% CI 2–5%) among all bloodstream infections (BSIs) and 44% (95% CI 32–57%) among S. aureus bacteremia in cancer patients. Based on geographical stratification, the pooled prevalence was 5% in Africa (95% CI 1–14%), 1% in Americas (95% CI 1–2%), 2% in Europe (95% CI 1–4%), 4% in Western Pacific (95% CI 2–7%), 8% in South-east Asia (95% CI 4–14%) and 0% in Eastern Mediterranean (95% CI 0–3%). No significant temporal change in MRSA rates was detected in this analysis (R2 = 0.06; P=0.24). Predictors for MRSA BSIs among cancer patients were identified by comparison with their methicillin-susceptible counterparts, and they were mainly related to healthcare-associated infections and immunosuppression. Finally, the 60-day mortality in adult cancer patients with MRSA BSIs was reported to be 12%, and the 6-month overall mortality was 43.2%, with community-onset infection, secondary BSI, and vancomycin MIC≥2g/mL being the risk factors for mortality.Conclusions: Although the prevalence of MRSA BSIs among cancer patients is relatively low, it did not decline over time as MRSA BSIs in the general hospital population and the high mortality rate was related to MRSA BSIs in patients with malignancy.

Download Full-text

Prevalence, Predictors, and Mortality of Bloodstream Infections Due to Methicillin-Resistant Staphylococcus Aureus in Patients with Malignancy: Systemic Review and Meta-Analysis

10.21203/rs.3.rs-38902/v1 ◽

2020 ◽

Author(s):

Zhouqi Li ◽

Hemu Zhuang ◽

Guannan Wang ◽

Hui Wang ◽

Ying Dong

Keyword(s):

Staphylococcus Aureus ◽

Cancer Patients ◽

Methicillin Resistant Staphylococcus Aureus ◽

Eastern Mediterranean ◽

Meta Analysis ◽

Bloodstream Infections ◽

Systemic Review ◽

Primary Data ◽

Methicillin Resistant ◽

Pooled Prevalence

Abstract Background: Cancer patients are more likely to develop and die of bloodstream infection (BSI) than noncancer patients. Methicillin-resistant Staphylococcus aureus (MRSA), which is associated with immense mortality and economic burden worldwide, is not covered by the recommended initial antibiotic therapy for cancer patients with BSI. This systemic review was performed to estimate the global methicillin-resistant Staphylococcus aureus (MRSA) prevalence among bacteremia in patients with malignancy, and further study the predictors and mortality of cancer patients with MRSA bacteremia. Methods: The PubMed and EMBASE databases were searched for studies published from Jan. 2000 to Mar. 2020 that provided primary data on the prevalence, predictors, or mortality of MRSA bacteremia in cancer patients. A random-effects model meta-analysis was performed to estimate the pooled prevalence of MRSA with 95% confidence intervals (95% CIs).Results: The pooled prevalence of MRSA was 3% (95% CI 2–5%) among all bloodstream infections (BSIs) and 44% (95% CI 32–57%) among S. aureus bacteremia in cancer patients. Based on geographical stratification, the pooled prevalence was 5% in Africa (95% CI 1–14%), 1% in Americas (95% CI 1–2%), 2% in Europe (95% CI 1–4%), 4% in Western Pacific (95% CI 2–7%), 8% in South-east Asia (95% CI 4–14%) and 0% in Eastern Mediterranean (95% CI 0–3%). No significant temporal change in MRSA rates was detected in this analysis (R2 = 0.06; P=0.24). Predictors for MRSA BSIs among cancer patients were identified by comparison with their methicillin-susceptible counterparts, and they were mainly related to healthcare-associated infections and immunosuppression. Finally, the 60-day mortality in adult cancer patients with MRSA BSIs was reported to be 12%, and the 6-month overall mortality was 43.2%, with community-onset infection, secondary BSI, and vancomycin MIC≥2g/mL being the risk factors for mortality.Conclusions: Although the prevalence of MRSA BSIs among cancer patients is relatively low, it did not decline over time as MRSA BSIs in the general hospital population and the high mortality rate was related to MRSA BSIs in patients with malignancy.

Download Full-text

Prevalence of Staphylococcus aureus Nasal Carriage and Methicillin-resistant Staphylococcus aureus Among Medical Students: A Systematic Review and Meta-analysis

Jundishapur Journal of Microbiology ◽

10.5812/jjm.111125 ◽

2021 ◽

Vol 13 (11) ◽

Author(s):

Yasaman Abdoli Oskouie ◽

Masoumeh Abbassi ◽

Ali Taghavi Zonouz ◽

Fariba Pashazadeh ◽

Shahram Abdoli Oskouie ◽

...

Keyword(s):

Staphylococcus Aureus ◽

Medical Students ◽

Subgroup Analysis ◽

Prevalence Rate ◽

Methicillin Resistant Staphylococcus Aureus ◽

Meta Analysis ◽

Nasal Carriage ◽

Prevalence Rates ◽

Methicillin Resistant ◽

Pooled Prevalence

Context: Evaluating the prevalence of Staphylococcus aureus nasal carriage and methicillin-resistant Staphylococcus aureus (MRSA) that are sources of nosocomial infection among medical students. Evidence Acquisition: Electronic databases were searched by preferred subject headings and free-text keywords. After omitting duplicates, retrieved articles were screened by two independent reviewers in a three-step process based on inclusion criteria. Then, reviewers critically appraised the selected studies by JBI checklists and extracted the required data. Finally, the pooled prevalence rates of S. aureus nasal carriage and MRSA were meta-analyzed by Stata V.16 software. The heterogeneity of included studies was calculated by I2 and chi-square. Subgroup analysis was carried out according to study designs, as well as the continent origin of clinical and preclinical students. Results: Of 858 retrieved studies, 15 were included in the meta-analysis. The results showed that the pooled prevalence of nasal S. aureus carriage was 28% [prevalence rate: 0.028, 95% CI: 0.21 - 0.34, P < 0.001, I2: 96.40%, chi2: 360.98 (df = 14)]. The prevalence of S. aureus among clinical students was 33% (pooled prevalence rate: 0.33, 95% CI: 0.18 - 0.47) whereas, in preclinical students, it was 25% (pooled prevalence rate: 0.25, 95% CI: 0.23 - 0.28). Also, in a subgroup analysis of continents, Australia (Oceania) had the highest prevalence rate. According to an evaluation of publication bias, the distribution of studies was very high. Moreover, pooled MRSA prevalence among medical students was 2% (prevalence rate: 0.02 95% CI: 0.01 - 0.03, P < 0.001). Conclusions: In this meta-analysis, S. aureus and MRSA prevalence rates among medical students were estimated at 28% and 2%, respectively. More attention should be given to the prevention of MRSA colonization and screening strategies among medical students across the world.

Download Full-text